Actavis, Harbin and Adamed in race for Polish drugmaker Polfa Warszawa?

Several pharmaceutical producers, among which are the Iceland-based generics major Actavis and China’s Harbin Gloria Pharmaceuticals, are in the race for Polfa Warszawa, one of Poland’s biggest pharmaceutical producers, which is expected to be sold by its current owner Poland’s Polski Holding Farmaceutyczny (PHF) in the second quarter of the current year.

Most local experts believe that domestic firm Adamed, as well as Actavis, have the greatest chance of acquiring Polfa Warszawa, which would help them to accelerate expansion into the Polish pharmaceutical market. It is estimated that the acquisition would cost around 500 million zlotys ($182.1 million). In the case of Adamed, in February 2010, the company acquired an 85% stake in one of PHF’s subsidiaries - Polfa Pabianice for 300 million zlotys.

Buyer could be Ukraine’s Arterium